Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.54 |
| ▸ | GRM8 | O00222 | 1/20 | 0.54 |
| ▸ | GRM6 | O15303 | 1/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.54 |
| ▸ | GSR | P00390 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.54 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.54 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.54 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14125401 | 0.94 | GRM8 (0.56) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL31206935 | 0.92 | GRM8 (0.67) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL20508769 | 0.92 | GRM8 (0.67) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL496858 | 0.92 | GRM8 (0.62) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL4959221 | 0.92 | GRM8 (0.62) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| Glutamic Acid SCHEMBL27517274 | 0.91 | GRM8 (0.64) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL7761327 | 0.90 | SLC1A1 (0.47) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL10636419 | 0.90 | GRM8 (0.60) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| Glutamic Acid SCHEMBL27775331 | 0.89 | GRM8 (0.62) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL1276948 | 0.89 | SLC1A1 (0.41) | SLC1A1GRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024190663-A1 | BIOMARKER AND USE THEREOF | 株式会社明治 | 2024-09-19 | — | — | WO | claimed |
| CN-117269494-A | A group of metabolic markers for breast cancer lung metastasis | 厦门大学 | 2023-12-22 | — | — | CN | claimed |
| CN-105683390-A | HbA1c measurement method using amadoriase acting on glycated peptides | 龟甲万株式会社 | 2016-06-15 | — | — | CN | claimed |
| EP-2661266-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Elcelyx Therapeutics, Inc. (US) | 2013-11-13 | — | — | EP | claimed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | claimed |
| JP-H09510696-A | — | — | 1997-10-28 | — | — | JP | claimed |
| EP-0737077-A1 | HEPATOCYTE-TARGETED DRUG CONJUGATES | TARGETECH, INC. (US) | 1996-10-16 | — | — | EP | claimed |
| WO-1995018636-A2 | HEPATOCYTE-TARGETED DRUG CONJUGATES | TARGETECH INC (US) | 1995-07-13 | — | — | WO | claimed |
| EP-3806661-B1 | USE OF ANTAGONISTS OF T2R54 | FIRMENICH INCORPORATED (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4566459-A2 | ANTAGONISTS OF T2R54 AND COMPOSITIONS AND USES THEREOF | Firmenich Incorporated (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12295396-B2 | Antagonists of T2R54 and compositions and uses thereof | FIRMENICH INCORPORATED (US) | 2025-05-13 | — | — | US | disclosed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119639611-A | Cryptosporidium-resistant synbiotic preparation and preparation method and application thereof | 中国农业大学 | 2025-03-18 | — | — | CN | disclosed |
| CN-119257964-A | Cleaning liquid capable of being washed-free or dry-cleaned and application thereof | 苏州欧丽特生物医药有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2004012662-A2 | IMPROVED TREATMENT OF CANCER WITH GLUTAMINE | AESGEN, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| US-20020147156-A1 | Cellular uptake of bioactive agents | EISAI INC. | 2002-10-10 | — | — | US | disclosed |
| EP-1206283-A2 | IMPROVED CELLULAR UPTAKE OF BIOACTIVE AGENTS | Aesgen, Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2000069470-A2 | IMPROVED CELLULAR UPTAKE OF BIOACTIVE AGENTS | AESGEN, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| EP-0737077-A1 | HEPATOCYTE-TARGETED DRUG CONJUGATES | TARGETECH, INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018636-A2 | HEPATOCYTE-TARGETED DRUG CONJUGATES | TARGETECH INC (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12295396-B2 | Antagonists of T2R54 and compositions and uses thereof | TAS2R50, TAS2R30, TAS2R60 | SLC1A1 476/4885GRM8 189/4885GRM6 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.